Policy Developments - The Ministry of Industry and Information Technology, along with two other departments, announced the initiation of the 2025 high-end medical equipment promotion application project [1] Drug and Device Approvals - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, aimed at treating cancer pain in adults, with no similar drugs currently on the market [2] - Heng Rui Medicine's subsidiary received approval for clinical trials of HRS-2129, targeting diabetic peripheral neuropathic pain and osteoarthritis pain, with a total R&D investment of approximately 112 million yuan [3] - Borui Pharmaceutical obtained FDA approval for the clinical trial of BGM1812 injection for overweight or obesity treatment, with no similar products approved globally [4] Capital Market - Hangzhou Yaojiasu Medical Isotope Technology Co., Ltd. announced the completion of several million yuan in angel round financing, aimed at expanding its core team and advancing technology development [5] Industry Events - The National Medical Insurance Administration has identified and addressed multiple cases of abnormal data, enhancing the regulatory capabilities of medical insurance data [7] - Xiangyu Medical signed a cooperation agreement with Zhejiang Provincial People's Hospital to establish a clinical research ward for brain-machine interfaces [8] - A micro "lung chip" with an embedded immune system was developed by researchers from Georgia Tech and Vanderbilt University, potentially revolutionizing disease research [9] Public Opinion Alerts - Shenqi Pharmaceutical faced a significant stock drop after being ordered to rectify issues related to the misappropriation of 44.83 million yuan in sales fees, leading to regulatory actions [10]

Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]

Core Viewpoint - The company, Borui Pharmaceutical, has received approval from the U.S. FDA to initiate Phase I clinical trials for BGM1812 injection aimed at treating overweight or obesity [2] Group 1 - The announcement was made on the evening of September 29 [2] - The approval marks a significant step for the company in the development of treatments for obesity [2]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月29日，博瑞医药发布公告称，公司获美国FDA（美国 食品药品监督管理局）批准开展BGM1812注射液用于超重或肥胖治疗的I期临床。 公告显示，BGM1812注射液是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药学稳 定性。Amylin（胰淀素）作为一种由37个氨基酸组成的饱腹感多肽激素，由胰腺β细胞与胰岛素协同释 放入血。它通过激活大脑饱腹感通路抑制食欲，同时延缓胃排空、抑制胰高血糖素分泌，具有多重减重 机制。 ...

每经AI快讯，9月29日，博瑞医药(688166.SH)公告称，公司获美国FDA批准开展BGM1812注射液用于 超重或肥胖治疗的I期临床。BGM1812注射液是公司优化设计的新型长效Amylin类似物，具有良好的分 子活性和药学稳定性。Amylin(胰淀素)作为一种由37个氨基酸组成的饱腹感多肽激素，由胰腺β细胞与 胰岛素协同释放入血。它通过激活大脑饱腹感通路抑制食欲，同时延缓胃排空、抑制胰高血糖素分泌， 具有多重减重机制。BGM1812注射液减重适应症在中国已递交临床试验申请，目前正在审评中。截至 本公告披露日，全球尚无同类靶点制剂减重适应症获批上市。 ...

BGM1812注射液是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药学稳定性。 Amylin(胰淀素)作为一种由37个氨基酸组成的饱腹感多肽激素，由胰腺β细胞与胰岛素协同释放入血。 它通过激活大脑饱腹感通路抑制食欲，同时延缓胃排空、抑制胰高血糖素分泌，具有多重减重机制。 智通财经APP讯，博瑞医药(688166.SH)发布公告，公司获美国FDA(即美国食品药品监督管理局)批准开 展BGM1812注射液用于超重或肥胖治疗的I期临床。 ...

博瑞医药公告，公司获美国FDA批准开展BGM1812注射液用于超重或肥胖治疗的I期临床。BGM1812注 射液是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药学稳定性。Amylin（胰淀 素）作为一种由37个氨基酸组成的饱腹感多肽激素，由胰腺β细胞与胰岛素协同释放入血。它通过激活 大脑饱腹感通路抑制食欲，同时延缓胃排空、抑制胰高血糖素分泌，具有多重减重机制。 ...

Core Viewpoint - The innovative drug sector has emerged as one of the brightest segments in the Hong Kong stock market this year, with significant recognition from international capital reflected in the performance of the Hong Kong innovative drug ETF, which has seen a year-to-date increase of over 100% and a maximum increase exceeding 130% [3][4]. Group 1: Market Performance and Investor Dynamics - The Hong Kong stock market, primarily driven by institutional investors, has benefited from deep international capital participation, enhancing pricing efficiency and aligning stock prices closer to intrinsic values [4]. - The continuous inflow of southbound funds has strengthened the correlation between Hong Kong and A-share markets, providing important value references for A-shares [4]. - Notable companies like 恒瑞医药 (Hengrui Medicine) and 宁德时代 (CATL) have seen their H-shares trading at significantly higher prices than their A-shares, indicating a willingness in the Hong Kong market to pay higher valuation premiums for quality enterprises [5]. Group 2: Company-Specific Developments - 博瑞医药 (Borui Medicine) has announced plans to issue H-shares and list on the Hong Kong Stock Exchange, marking a step towards deeper engagement with international capital [5][6]. - The anticipated use of funds from the H-share issuance is likely focused on drug research and development, particularly for the GLP-1 series innovative drugs, with significant ongoing clinical trials [6][7]. - In the first half of the year, 博瑞医药's R&D investment reached 348 million, a year-on-year increase of 144.07%, representing approximately 65% of its total revenue for that period [7][10]. Group 3: R&D Strategy and Pipeline - 博瑞医药's current pipeline includes several innovative drugs targeting weight loss and diabetes, with the BGM0504 injection having entered Phase III clinical trials [6][21]. - The company is actively pursuing an integrated strategy for raw materials and formulations, necessitating substantial capital investment to maintain its competitive edge in GLP-1 research and development [13][24]. - The R&D intensity of 博瑞医药 is comparable to many innovative pharmaceutical companies that have not yet commercialized their products, indicating a strong focus on future growth despite current financial pressures [8][11]. Group 4: Competitive Landscape - 博瑞医药's product matrix is strategically designed to address different patient demographics, with specific formulations targeting both low and high weight loss needs [21]. - The company aims to differentiate itself in the competitive GLP-1 market by developing unique formulations and leveraging advanced technologies for oral drug delivery, which could significantly enhance patient compliance and treatment outcomes [22][23]. - Clinical data from 博瑞医药's BGM0504 injection shows promising results, with a weight reduction of 18.5% and a significant percentage of patients achieving substantial weight loss [22].

Market Performance - The A-share market indices collectively rose during the week of September 22 to September 26, with the Shanghai Composite Index closing at 3828.11 points, up 0.21% for the week [1] - The Shenzhen Component Index closed at 13209.00 points, up 1.06%, while the ChiNext Index closed at 3151.53 points, up 1.96% [1] - Over 30% of stocks experienced gains, with 126 stocks rising over 15% and 50 stocks declining over 15% [1] Top Gainers - Bluefeng Biochemical (002513.SZ) led the gainers with a weekly increase of 61.16%, followed by Sunflower (300111.SZ) with a 57.86% rise [2] - Other notable gainers included Jucheng Technology (688123.SH), Changchuan Technology (300604.SZ), and Fuke Environmental Protection (688335.SH), all with gains exceeding 44% [2] - Bluefeng Biochemical is a major domestic producer of pesticides, and it recently established a subsidiary focused on high-efficiency N-type crystalline silicon photovoltaic products [2][3] Top Losers - Borui Pharmaceutical (688166.SH) was the biggest loser, with a decline of 38.36% [5] - Other significant decliners included Xiangjiang Holdings (600162.SH) and Haotaitai (603848.SH), both with declines over 22% [5] - Borui Pharmaceutical's stock price fell to 58.06 yuan per share, with a 12.57% drop on September 26 alone [6] Company Developments - Borui Pharmaceutical announced a stock repurchase plan, proposing to buy back shares worth between 10 million and 20 million yuan [9] - The company is progressing with its overseas market expansion, with several clinical trials ongoing for its weight loss products in the U.S. [8][9] - Pfizer's acquisition of Metsera for $7.3 billion has impacted Borui Pharmaceutical's stock, signaling a shift in market expectations for weight loss drug development [10]